Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) updated its FY 2022 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.800-$0.850 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.900. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.17 […]
Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) traded down 8.1% during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $4.05 and last traded at $4.09. 2,359 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 491,801 shares. The stock had […]
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) updated its FY 2022 earnings guidance on Wednesday. The company provided EPS guidance of $0.800-$0.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.900. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.17 billion.Amneal Pharmaceuticals also updated […]
The Manufacturers Life Insurance Company reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) by 5.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,194 shares of the company’s stock after selling 3,125 shares during the period. The […]